NASDAQ:CAPR
Capricor Therapeutics Stock News
$5.24
-0.0900 (-1.69%)
At Close: May 02, 2024
Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial
12:22pm, Monday, 28'th Mar 2022
Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients. Capricor s
Capricor Stops Work On Exosome-mRNA Based COVID-19 Vaccine Candidate
06:29pm, Friday, 11'th Mar 2022 Benzinga
In its Q4 FY21 earnings press release , Capricor Therapeutics Inc (NASDAQ: CAPR ) said it had halted work on the exosome-based jab due to the "current availability of vaccines for" COVID-19, Capricor said. Instead, the Company will focus its resources on CAP-1002 and announce the Lancet publication of Phase 2 trial results for the Duchenne muscular dystrophy (DMD) treatment CAP-1002. According to the Lancet publication, after … Full story available on Benzinga.com
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q4 2021 Results - Earnings Call Transcript
10:57pm, Thursday, 10'th Mar 2022 Seeking Alpha
Capricor Therapeutics GAAP EPS of -$0.26
09:07pm, Thursday, 10'th Mar 2022 Seeking Alpha
Capricor Therapeutics press release (CAPR): Q4 GAAP EPS of -$0.26.Company’s cash and cash equivalents totaled approximately $34.9 million as of December 31, 2021, compared…
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
09:01pm, Thursday, 10'th Mar 2022 GlobeNewswire Inc.
CAP-1002 Cell Therapy Programs
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
09:01pm, Thursday, 10'th Mar 2022 GlobeNewswire
CAP-1002 Cell Therapy Programs
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q4 2021 Results - Earnings Call Transcript
05:57pm, Thursday, 10'th Mar 2022
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q4 2021 Results - Earnings Call Transcript
Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10
02:15pm, Thursday, 03'rd Mar 2022 GlobeNewswire Inc.
Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET
Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10
02:15pm, Thursday, 03'rd Mar 2022 GlobeNewswire
Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET
Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10
09:15am, Thursday, 03'rd Mar 2022
Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET
Thinking about buying stock in SoFi Technologies, Vinco Ventures, DiDi Global, Capricor Therapeutics, or ShiftPixy?
03:45pm, Tuesday, 25'th Jan 2022 Benzinga
NEW YORK , Jan. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOFI, BBIG, DIDI, CAPR, and PIXY. … Full story available on Benzinga.com
5 Hot Penny Stocks To Watch After Big News Today
02:32pm, Tuesday, 25'th Jan 2022 PennyStocks
5 hot penny stocks to watch after big news.
The post 5 Hot Penny Stocks To Watch After Big News Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
12:46pm, Tuesday, 25'th Jan 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate
Pfizer, Inc. (NYSE: PFE) and BioNT
Capricor Therapeutics, Nippon Shinyaku Ink US Pact For Duchenne Muscular Dystrophy Candidate
11:06am, Tuesday, 25'th Jan 2022
Capricor Therapeutics Inc (NASDAQ: CAPR) has partnered with Nippon Shinyaku Co Ltd for the exclusive commercialization and distribution in the U.S of Capricor's CAP-1002 for Duchenne muscular dys
Capricor jumps 12% after CAP-1002 commercialization deal in U.S. for treatment of DMD
10:38am, Tuesday, 25'th Jan 2022 Seeking Alpha
Capricor Therapeutics (CAPR) soars 12.4% premarket after entering into a partnership with Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company, for the exclusive
